Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eugenol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.80 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.80 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.80 |
| ▸ | AR | P10275 | 1/20 | 0.80 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.80 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.59 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.59 |
| ▸ | PPARA | Q07869 | 3/20 | 0.58 |
| ▸ | PPARG | P37231 | 1/20 | 0.58 |
| ▸ | PPARD | Q03181 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eugenol SCHEMBL2883800 | 0.94 | ALDH1A1 (0.90) | ALDH1A1ALOX5PTGS1CYP3A4AR | |
| Eugenol SCHEMBL114133 | 0.91 | ALDH1A1 (0.85) | ALDH1A1ALOX5PTGS1CYP3A4AR | |
| Eugenol SCHEMBL27608718 | 0.91 | ALDH1A1 (0.85) | ALDH1A1ALOX5PTGS1CYP3A4AR | |
| Eugenol SCHEMBL29943804 | 0.91 | ALDH1A1 (0.85) | ALDH1A1ALOX5PTGS1CYP3A4AR | |
| Eugenol SCHEMBL22719783 | 0.90 | ALDH1A1 (0.78) | ALDH1A1ALOX5PTGS1CYP3A4AR | |
| Eugenol SCHEMBL31189370 | 0.90 | ALDH1A1 (0.82) | ALDH1A1ALOX5PTGS1CYP3A4AR | |
| Eugenol SCHEMBL6152218 | 0.90 | ALDH1A1 (0.82) | ALDH1A1ALOX5PTGS1CYP3A4AR | |
| Eugenol SCHEMBL27710638 | 0.90 | ALDH1A1 (0.82) | ALDH1A1ALOX5PTGS1CYP3A4AR | |
| Eugenol SCHEMBL16433004 | 0.90 | ALDH1A1 (0.82) | ALDH1A1ALOX5PTGS1CYP3A4AR | |
| Eugenol SCHEMBL1289317 | 0.90 | ALDH1A1 (0.93) | ALDH1A1ALOX5PTGS1CYP3A4AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1530606-B1 | SILOXANE BISCHLOROFORMATES | SABIC INNOVATIVE PLASTICS IP (NL) | 2010-12-08 | — | — | EP | disclosed |
| US-6930194-B2 | Siloxane bischloroformates | GENERAL ELECTRIC COMPANY (US) | 2005-08-16 | — | — | US | disclosed |
| EP-1530606-A1 | SILOXANE BISCHLOROFORMATES | GENERAL ELECTRIC COMPANY (US) | 2005-05-18 | — | — | EP | disclosed |
| US-6833422-B2 | Interfacial polymerization of polycarbonates with polysiloxanes, then endcapping to form haze-free polycarbonatepolysiloxane copolymers | GENERAL ELECTRIC COMPANY | 2004-12-21 | — | — | US | disclosed |
| US-6723864-B2 | CONTINUOUS PROCESS BY PHOSGENATING SILOXANE BISPHENOLS IN A FLOW REACTOR USING A SUBSTANTIAL EXCESS OF PHOSGENE AND SODIUM HYDROXIDE | GENERAL ELECTRIC COMPANY | 2004-04-20 | — | — | US | disclosed |
| US-20040039145-A1 | Method of preparing transparent silicone-containing copolycarbonates | GENERAL ELECTRIC COMPANY | 2004-02-26 | — | — | US | disclosed |
| WO-2004016675-A1 | SILOXANE BISCHLOROFORMATES | GENERAL ELECTRIC COMPANY (US) | 2004-02-26 | — | — | WO | disclosed |
| US-20040039218-A1 | A continuous process by phosgenating siloxane bisphenols in a flow reactor using a substantial excess of phosgene and sodium hydroxide to achieve high yields and very pure product; intermediates for polycarbonatesiloxanes | GENERAL ELECTRIC COMPANY | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039218-A1 | A continuous process by phosgenating siloxane bisphenols in a flow reactor using a substantial excess of phosgene and sodium hydroxide to achieve high yields and very pure product; intermediates for polycarbonatesiloxanes | PSPH, PAH, SEM1 | ALDH1A1 4036/4885ALOX5 1919/4885PTGS1 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.